Cardio Diagnostics Inc. (CDIO)
NASDAQ: CDIO
· Real-Time Price · USD
4.14
0.08 (1.97%)
At close: Sep 26, 2025, 3:59 PM
4.05
-2.29%
After-hours: Sep 26, 2025, 05:56 PM EDT
Company Description
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test.
Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Cardio Diagnostics Inc.
| Country | United States |
| IPO Date | Jan 14, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Meeshanthini V. Dogan |
Contact Details
Address: 400 N Aberdeen St Chicago, Illinois United States | |
| Website | https://cardiodiagnosticsinc.com |
Stock Details
| Ticker Symbol | CDIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870144 |
| CUSIP Number | 14159C103 |
| ISIN Number | US14159C1036 |
| Employer ID | 87-0925574 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Meeshanthini V. Dogan Ph.D. | Co-Founder, Chief Executive Officer & Director |
| Elisa Michael Luqman Esq., J.D., M.B.A. | Chief Financial Officer & Principal Accounting Officer |
| Timur Dogan Ph.D. | Chief Technology Officer |
| Dr. Robert A. Philibert M.D., Ph.D. | Co-Founder, Chief Medical Officer & Director |
| Khullani Abdullahi J.D. | Vice President of Revenue & Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2025 | 424B3 | Filing |
| Sep 16, 2025 | POS AM | Filing |
| Sep 12, 2025 | 424B3 | Filing |
| Sep 05, 2025 | POS AM | Filing |
| Sep 04, 2025 | DEFA14A | Filing |
| Sep 04, 2025 | DEF 14A | Filing |
| Aug 27, 2025 | ARS | Filing |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 13, 2025 | PRE 14A | Filing |
| Jul 02, 2025 | 4 | Filing |